A more comprehensive assessment of individual genetic variation affecting AHR signaling is needed to fully delineate the role of AHR pharmacogenomics in the maintenance of intestinal homeostasis, the development and progression of IBD, and response to therapies. The gene discussed is AHR; the disease is inflammatory bowel disease.